CytomX Therapeutics Inc (CTMX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sean A. McCarthy
Employees:
170
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA 94080
650.515.3185

CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 98.739 Million Shares Outstanding65.39 Million Avg 30-day Volume 512.89 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue5.0154 Debt to Equity0.0 EBITDA-72.371 Million
Price to Book Value2.974 Operating Margin-109.11070000000001 Enterprise Value-4.14 Million
Current Ratio2.416 EPS Growth0 Quick Ratio2.377
1 Yr BETA 0.9402 52-week High/Low 7.53 / 1.19 Profit Margin-59.4029
Operating Cash Flow Growth162.7797 Altman Z-Score-1.1546 Free Cash Flow to Firm -99.004 Million
Earnings Report2022-11-03
View SEC Filings from CTMX instead.

View recent insider trading info

Funds Holding CTMX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CTMX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-09-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-13:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-03-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ROWLAND LLOYD A GENERAL COUNSEL

    • Officer
    157,500 2022-08-10 4

    MCCARTHY SEAN A. CEO

    • Officer
    • Director
    525,000 2022-08-10 5

    OGDEN CHRISTOPHER SVP, FINANCE AND ACCOUNTING

    • Officer
    96,250 2022-08-10 2

    LANDAU JEFFREY B CHIEF BUSINESS OFFICER

    • Officer
    157,500 2022-08-10 3

    HANNAH ALISON L. CHIEF MEDICAL OFFICER

    • Officer
    31,898 2022-07-19 3

    PETERSON AMY C. EVP, CHIEF DEVELOPMENT OFFICER

    • Officer
    62,690 2022-07-19 3

    CAMPOY CARLOS CHIEF FINANCIAL OFFICER

    • Officer
    39,972 2022-07-19 3

    GLUCK FREDERICK W

    • Director
    25,000 2022-06-15 1

    JONES ELAINE V

    • Director
    25,000 2022-06-15 1

    MEYERS JAMES R

    • Director
    25,000 2022-06-15 1

    GILBERT HALLEY E

    • Director
    25,000 2022-06-15 1

    YOUNG MATTHEW P.

    • Director
    25,000 2022-06-15 1

    MOHINDRU MANI

    • Director
    25,000 2022-06-15 1

    ASHWORTH ALAN

    • Director
    25,000 2022-06-15 1

    SCARLETT JOHN A

    • Director
    20,000 2021-06-16 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2021-01-25 0

    FUCHS CHARLES S.

    • Director
    0 2020-06-17 0

    KAVANAUGH WILLIAM MICHAEL CSO, HEAD RES.&NON-CLIN. DEV.

    • Officer
    0 2020-02-14 0

    KNIFSEND ROBIN PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2020-02-14 0

    HUMPHREY RACHEL CHIEF MEDICAL OFFICER

    • Officer
    0 2019-01-25 0

    RAY DEBANJAN CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-01-25 0

    HUH HOYOUNG

    • Director
    0 2018-06-13 0

    THIRD ROCK VENTURES LP

    THIRD ROCK VENTURES GP, L.P.

    TRV GP, LLC

    LEVIN MARK J

    STARR KEVIN P

    TEPPER ROBERT I

    • 10% Owner
    No longer subject to file 2017-10-18 0

    TEPPER ROBERT I

    • 10% Owner
    4,349,864 2017-10-04 0

    EXTER NEIL

    • Director
    0 2017-06-20 0

    MCCOURT MARION

    • Director
    0 2017-06-20 0

    GOELTZ II ROBERT C. CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2017-05-12 0

    STARR KEVIN P

    • 10% Owner
    5,201,767 2017-04-12 0

    CANAAN IX L.P.

    CANAAN PARTNERS IX LLC

    • Director
    2,494,381 2017-03-27 0

    LADD CYNTHIA J SENIOR VP AND GENERAL COUNSEL

    • Officer
    0 2017-01-25 0

    SHANNON TIMOTHY M

    • Director
    3,244,829 2016-11-29 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    No longer subject to file 2015-10-14 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    No longer subject to file 2015-10-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MCCARTHY SEAN A. - Director - Officer CEO

    2022-08-12 17:01:21 -0400 2022-08-10 A 450,000 a 450,000 direct

    MCCARTHY SEAN A. - Director - Officer CEO

    2022-08-12 17:01:21 -0400 2022-08-10 A 75,000 a 75,000 direct

    LANDAU JEFFREY B - Officer CHIEF BUSINESS OFFICER

    2022-08-12 17:00:43 -0400 2022-08-10 A 135,000 a 135,000 direct

    LANDAU JEFFREY B - Officer CHIEF BUSINESS OFFICER

    2022-08-12 17:00:43 -0400 2022-08-10 A 22,500 a 22,500 direct

    OGDEN CHRISTOPHER - Officer SVP, FINANCE AND ACCOUNTING

    2022-08-12 16:59:33 -0400 2022-08-10 A 82,500 a 82,500 direct

    OGDEN CHRISTOPHER - Officer SVP, FINANCE AND ACCOUNTING

    2022-08-12 16:59:33 -0400 2022-08-10 A 13,750 a 13,750 direct

    ROWLAND LLOYD A - Officer GENERAL COUNSEL

    2022-08-12 16:58:40 -0400 2022-08-10 A 135,000 a 135,000 direct

    ROWLAND LLOYD A - Officer GENERAL COUNSEL

    2022-08-12 16:58:40 -0400 2022-08-10 A 22,500 a 22,500 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 22:15:03 UTC 2.4284 0.6416 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 21:45:03 UTC 2.6453 0.4247 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 21:15:04 UTC 2.6453 0.4247 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 20:45:03 UTC 2.6514 0.4186 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 20:15:04 UTC 2.6514 0.4186 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 19:45:04 UTC 2.6514 0.4186 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 19:15:04 UTC 2.6514 0.4186 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 18:45:03 UTC 2.6444 0.4256 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 18:15:03 UTC 2.6444 0.4256 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 17:45:03 UTC 2.6444 0.4256 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 17:15:03 UTC 2.6444 0.4256 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 16:45:04 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 16:15:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 15:45:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 15:15:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 14:45:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 14:15:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 13:45:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 13:15:03 UTC 2.3053 0.7647 1200000
    CYTOMX THERAPEUTICS INC CTMX 2022-10-05 12:45:03 UTC 2.3053 0.7647 1100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund CTMX -1.0 shares, $-7.67 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund CTMX -3.0 shares, $-23.01 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments